Trusted Resources: News & Events
Latest announcements and gatherings
bluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug Product in Patients with Transfusion-Dependent β-Thalassemia (TDT) and Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
First patient with severe sickle cell disease treated with gene therapy remains free of clinical symptoms 21 months after receiving LentiGlobin Drug Product.
Ongoing transfusion independence and sustained production of HbAT87Q in patients with transfusion-dependent β-thalassemia.
Company to host event at ASH with live webcast, Monday, December 5 at 8:30 p.m. PT.
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced the presentation of new data from the ongoing HGB-205 clinical study evaluating its LentiGlobin product candidate in patients with transfusion-dependent β-thalassemia (TDT) and severe sickle cell disease (SCD) at the 58th American Society of Hematology Annual Meeting.
+myBinderRelated Content
-
Hemoglobin A1c and Fructosamine Correlate in a Patient With Sickle Cell Disease And Diabetes on Chronic Transfusion ...In patients with sickle cell disease (SC...
-
A Validated Measure of Adherence to Antibiotic Prophylaxis in Children With Sickle Cell DiseaseAntibiotic prophylaxis is a mainstay in ...
-
Experimental Gene Therapy Reverses Sickle Cell Disease for YearsA study of an investigational gene thera...
-
WNY Girl Gets First Pediatric Bone Marrow Transplant for Sickle Cell in BuffaloKayla Rushing is the first pediatric pat...
-
New Sickle Cell Disease Research Shows Improved Patient OutcomesEmerging therapies and promising new ins...
-
Prodigy’s death shines light on slow progress against sickle cell diseaseThe death of the rap artist Prodigy (Alb...
-
HHS Secretary Alex Azar Touts White House Efforts to Fight Sickle Cell DiseaseBy 2029, Americans with sickle cell dise...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.